Related Experiment Videos
HRAS protooncogene polymorphism and breast cancer
P A Garrett1, B S Hulka, Y L Kim
1Department of Epidemiology, University of North Carolina School of Public Health, Chapel Hill 27599.
Summary
Rare HRAS alleles are linked to increased breast cancer risk, particularly in Black women and those with aggressive, hormone receptor-negative tumors. These alleles may serve as a future breast cancer screening biomarker.
Area of Science:
- Oncology
- Genetics
- Epidemiology
Background:
- The association between HRAS protooncogene polymorphisms and cancer susceptibility is debated due to inconsistent study findings.
- Previous research has yielded conflicting results regarding the link between HRAS gene variations and cancer risk.
Purpose of the Study:
- To investigate the specific association between rare HRAS alleles and breast cancer risk.
- To clarify the controversial link between HRAS gene variations and cancer susceptibility.
Main Methods:
- A multidisciplinary study combining molecular analysis and epidemiological data collection.
- Involved 160 breast cancer cases and 405 controls, with data collected via questionnaires and DNA analysis from peripheral blood.
- Controls were frequency-matched to cases based on age and race.
Main Results:
- A significant overall association was found between rare HRAS alleles and breast cancer.
- The association was stronger in specific control groups (OR=3.0, P<0.01; OR=2.0, P<0.05) and notably higher in Black women (3-6 times) compared to white women.
- Rare HRAS alleles correlated with hormone receptor-negative tumors, especially in Black and younger women.
Conclusions:
- Rare HRAS alleles are associated with an increased risk of breast cancer.
- This association appears stronger in Black women and may indicate a predisposition to more aggressive tumors in Black and younger women.
- HRAS alleles show potential as a screening biomarker for identifying women at higher risk for breast cancer.